Fulcrum Therapeutics Inc
(NAS:FULC)
$
9.17
0.38 (4.32%)
Market Cap: 572.22 Mil
Enterprise Value: 308.09 Mil
PE Ratio: 0
PB Ratio: 2.09
GF Score: 53/100 - Q1 2024 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 13, 2024$7.35 (-1.61%)Earnings
- Q4 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptFeb 27, 2024$10.18 (+4.62%)Earnings
- Q3 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 07, 2023$4.29 (+19.50%)Earnings
- Q2 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 03, 2023$3.85 (+0.79%)Earnings
- Q1 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 15, 2023$3.64 (+11.31%)Earnings
- Q4 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 09, 2023$4.82 (-23.00%)Earnings
- Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Fulcrum Therapeutics Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Q3 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 08, 2022$6.45 (+14.97%)Earnings
- Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 11, 2022$7.57 (-2.45%)Earnings
- Fulcrum Therapeutics Inc To Review Initial FTX-6058 Data And Provide Program Update Call TranscriptJun 10, 2022
- Fulcrum Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 09, 2022$7.66 (-11.24%)Earnings
- Fulcrum Therapeutics Inc To Discuss Unmet Need In FSHD, REACH Trial And Key Measures Of Disease Progression Call TranscriptMar 24, 2022
- Q4 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 03, 2022$11.7 (+5.41%)Earnings
- Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Fulcrum Therapeutics Inc To Discuss Phase 1 Clinical Trial of FTX-6058 Call TranscriptDec 06, 2021
- Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2021
- Q3 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 04, 2021$21.15 (+3.27%)Earnings
- Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 10, 2021$18.77 (+125.33%)Earnings
- Fulcrum Therapeutics Inc Annual FSHD Society International Research Congress- Corporate Call TranscriptJun 24, 2021
- Fulcrum Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q1 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 06, 2021$10.58 (+5.06%)Earnings
- Q4 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 04, 2021$12.5 (-14.32%)Earnings
- Fulcrum Therapeutics, Inc. - Special Call TranscriptDec 15, 2020
- Q3 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 10, 2020$10.94 (+1.11%)Earnings
- Q2 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 11, 2020$8.9 (-48.01%)Earnings
- Fulcrum Therapeutics, Inc. - Special Call TranscriptJun 10, 2020
- Fulcrum Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 13, 2020$16.48 (+10.53%)Earnings
- Q4 2019 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 05, 2020$18.5 (+2.78%)Earnings
- Q3 2019 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 14, 2019$7.64 (-3.29%)Earnings
Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021 / 09:20PM GMT
Release Date Price:
$18.28
(-3.94%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
Hi, everyone, and welcome to the final session of the 2021 Crédit Suisse Healthcare Conference. We're excited to have Bryan Stuart, President and CEO; and Chris Morabito, Chief Medical Officer, with us from Fulcrum. If anyone in the audience does have questions, you can certainly send them to me via email, [email protected], and I'll be sure to get those asked on your behalf. But we've got a long list here. So why don't we just jump in?
Questions & Answers
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
I thought we could start with a little bit of background on the FulcrumSeek platform, and how it differentiates your discovery process versus competitors?
Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director
Yes. And Judah, thank you. We appreciate the time. We appreciate everybody tuning in. So Fulcrum was started about 6
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)